# Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients

> **NCT00373646** · PHASE2 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 8 (actual)

## Conditions studied

- MALT Lymphoma

## Interventions

- **DRUG:** Thalidomide, Pharmion

## Key facts

- **NCT ID:** NCT00373646
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2009-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00373646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00373646, "Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00373646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*